Hoek Keith S, Eichhoff Ossia M, Schlegel Natalie C, Döbbeling Udo, Kobert Nikita, Schaerer Leo, Hemmi Silvio, Dummer Reinhard
Department of Dermatology, University Hospital of Zürich, Switzerland.
Cancer Res. 2008 Feb 1;68(3):650-6. doi: 10.1158/0008-5472.CAN-07-2491.
Metastatic melanoma represents a complex and heterogeneous disease for which there are no therapies to improve patient survival. Recent expression profiling of melanoma cell lines identified two transcription signatures, respectively, corresponding with proliferative and invasive cellular phenotypes. A model derived from these findings predicts that in vivo melanoma cells may switch between these states. Here, DNA microarray-characterized cell lines were subjected to in vitro characterization before s.c. injection into immunocompromised mice. Tumor growth rates were measured and postexcision samples were assessed by immunohistochemistry to identify invasive and proliferative signature cells. In vitro tests showed that proliferative signature melanoma cells are faster growing but less motile than invasive signature cells. In vivo proliferative signature cells initiated tumor growth in 14 +/- 3 days postinjection. By comparison, invasive signature cells required a significantly longer (P < 0.001) period of 59 +/- 11 days. Immunohistochemistry showed that regardless of the seed cell signature, tumors showed evidence for both proliferative and invasive cell types. Furthermore, proliferative signature cell types were detected most frequently in the peripheral margin of growing tumors. These data indicate that melanoma cells undergo transcriptional signature switching in vivo likely regulated by local microenvironmental conditions. Our findings challenge previous models of melanoma progression that evoke one-way changes in gene expression. We present a new model for melanoma progression that accounts for transcription signature plasticity and provides a more rational context for explaining observed melanoma biology.
转移性黑色素瘤是一种复杂的异质性疾病,目前尚无改善患者生存率的治疗方法。最近对黑色素瘤细胞系的表达谱分析分别鉴定出两种转录特征,分别与增殖性和侵袭性细胞表型相对应。基于这些发现得出的一个模型预测,体内黑色素瘤细胞可能在这些状态之间转换。在此,对经DNA微阵列表征的细胞系进行体外表征,然后皮下注射到免疫缺陷小鼠体内。测量肿瘤生长速率,并通过免疫组织化学评估切除后的样本,以鉴定侵袭性和增殖性特征细胞。体外试验表明,增殖性特征黑色素瘤细胞生长速度更快,但运动能力比侵袭性特征细胞弱。体内增殖性特征细胞在注射后14±3天开始形成肿瘤。相比之下,侵袭性特征细胞需要显著更长(P<0.001)的59±11天时间。免疫组织化学显示,无论种子细胞特征如何,肿瘤都显示出增殖性和侵袭性细胞类型的证据。此外,在生长肿瘤的外周边缘最常检测到增殖性特征细胞类型。这些数据表明,黑色素瘤细胞在体内经历转录特征转换,可能受局部微环境条件调控。我们的发现挑战了之前认为基因表达单向变化的黑色素瘤进展模型。我们提出了一种新的黑色素瘤进展模型,该模型考虑了转录特征可塑性,并为解释观察到的黑色素瘤生物学现象提供了更合理的背景。